Review: TROP-2 as potential new target for prostate cancer therapies
There are many companies working on TROP-2, mainly as antibody-drug conjugates and even if it's not very widespread in the context of prostate cancer, it is starting to gain traction.
Trop-2 is a promising therapeutic target in prostate cancer, particularly in aggressive subtypes like castration-resistant
There are many companies working on TROP-2, mainly as antibody-drug conjugates and even if it's not very widespread in the context of prostate cancer, it is starting to gain traction.
Trop-2 is a promising therapeutic target in prostate cancer, particularly in aggressive subtypes like castration-resistant